CML primary cells were exposed to 2 μM JNJ-165 for 72 hours, the viability of cells from the CML-CP patients with BCR/ABL positive and CML AP/BP patients was reduced by 32.9% and 23.4%, respectively, compared with cells from the patients with very low or undetectable BCR/ABL (Figure 1A). The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.